Alzheimer's Association criticises Nymox:
This article was originally published in Clinica
Executive Summary
The US Alzheimer's Association has recommended against using Nymox' AD7C test. The association says there is no published data on the test's ability to rule out Alzheimer's disease and describes Nymox' marketing as aggressive and objectionable. The test detects neural thread proteins, which the Alzheimer's Association says is also found in people with brain tumours and stoke victims. Nymox promotes the test directly on the World Wide Web.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.